Sebia and Metafora biosystems enter into a strategic collaboration to establish a range of in-vitro diagnostics (IVD) products.
FREMONT, CA: Sebia, a global pioneer in multiple myeloma and chronic illness diagnostics, and Metafora biosystems (Metafora), enters a strategic collaboration to establish a range of in-vitro diagnostics (IVD) products based on Metaforas technological platform. For the diagnosis of cellular metabolism abnormalities, Metafora uses a single-cell AI-powered diagnostic platform. Sphinx, Sebia's parent firm, has purchased a minority stake in Metafora as part of the agreement.
Jean-Marc Chermette, Chairman and CEO of Sebia, said, "We are excited to partner with Metafora biosystems, and to apply their innovative technology to make significant strides in the field of cancer and metabolic disease diagnostics. Our initial focus will be on applications in the diagnosis of multiple myeloma, where Sebia is the world leader, and we then expect to work together in other therapeutic areas."
Vincent Petit, co-founder and CEO of Metafora, said, "Sebia's commitment, both strategically and financially, is a key milestone in Metaforas development and highlights and validates the potential of our platform. Sebia's investment enables us to accelerate our R&D programs and prepare for commercial launches between now and 2023. We look forward to collaborating with Sebia's team and learning from their wealth of expertise in diagnostics to accelerate our development.
Sebia and Metafora's collaboration is focused on the development of new analytical procedures, particularly in haematology. The absence of reliable diagnostic tests to build informed therapeutic decisions still exists in hemato-oncology, and the two partners hope to address this gap.
Pierre Sonigo, Chief Scientific Officer of the Sebia Group, said, "Metafora's technology achieves the equivalent of a PET-Scan, the reference technology for cancer imaging, on "liquid biopsies", i.e., from a simple blood sample. The resolution of this analysis, which is based on flow cytometry, is the highest achievable since the sample is analyzed at a single cell level. This partnership expands the range of Sebia's electrophoresis and mass spectrometry technologies, optimizing the diagnosis and monitoring of cancers and chronic diseases".